BioSpace News Archive

CB Therapeutics is a leading synthetic biotechnology company focused on the research and development of cellular agriculture for the production of cannabinoids, tryptamines and other therapeutics to advance Neuroscience.

EMTensor, a global leader in Electromagnetic Tomography (ET) imaging solutions, and QuantalRF, an innovator in breakthrough wireless RF technology, today announced that the companies have signed an agreement to jointly evaluate QuantalRF’s Quantal technology within EMTensor’s Generation 4 ET brain scanning device.

Quantum Leap Healthcare Collaborative (QLHC), a non-profit organization focused on uniting patient care and research, and sponsor of the adaptive platform I-SPY 2 Trial™, announced today a unique pre-competitive consortium created for an I-SPY COVID Trial to rapidly identify therapies to treat acute respiratory distress syndrome (ARDS) in critically ill COVID-19 patients.

Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today that it has received clearance from the U.S. Food & Drug Administration (FDA) to market implant and instrument additions to the ARx Spinal System.

Sensiva Health is pleased to announce its substantial capacity for COVID-19 testing at this time and its anticipated ability to rapidly scale that capacity to help meet the volume of COVID-19 testing needed in the United States to allow for a safe social reopening.

The low-cost, scalable solution monitors critical treatment assets - like pharmaceuticals, consumables and medical equipment - from manufacture through delivery.

In recognition of Skin Cancer Awareness Month in May, dermatologists remind the public to #PracticeSafeSun to reduce their risk of skin cancer

Median Technologies (Paris:ALMDT) (ALMDT), The Imaging Phenomics Company®, provides an update on its performance for Q1 2020 and a review of its commitment to tackle Covid-19.

F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2™) antibodies, today announces the publication of preclinical data on the focused, potent and safe immune response shown with FS222 in leading peer-reviewed journal Clinical Cancer Research.

In a letter to Gov. Doug Ducey of Arizona, the Association of American Physicians and Surgeons (AAPS) presents a frequently updated table of studies that report results of treating COVID-19 with the anti-malaria drugs chloroquine (CQ) and hydroxychloroquine (HCQ, Plaquenil®).